BIOLOG-ID
23.11.2021 15:18:11 CET | Business Wire | Press release
As part of the biolog-id international deployment and in its preparation for going public, the company’s board of directors have designated Troy Hilsenroth as CEO of biolog-id worldwide. This appointment is effective since November 1st , 2021.
Fortified by 29 years of experience, Troy Hilsenroth has in-depth healthcare expertise. Before joining biologid as CEO of biolog-id LLC North-America in 2019, he was previously vice president and general manager of the medication adherence division at Omnicell, where he built and grew a global division over the last 10 years. Prior to this, he led management and staff pharmacy positions at renowned healthcare organizations.
“After 2 years as CEO for the North American region, I’m very proud and excited to take the lead of all biolog-id activities”, declare Troy Hilsenroth. “From the very beginning, I’m convinced that biolog-id has a significant potential to contribute to the digital transformation of the healthcare industry and I am very honored to take on this new position to support the company in its preparation for going public. I’m looking forward to – together with the Board and all collaborators – writing the next chapter of this success story”.
“As founder and Chairman of the Board of the company, I’m delighted to have Troy Hilsenroth taking these new responsibilities”, announces Jean-Claude Mongrenier. “The previous years spent in the company proven that Troy has a leading vision on how to develop our business, he has successfully deployed our solutions at major US Blood Banking institutions. We all agreed that Troy Hilsenroth is a standout leader, and the Board is confident that he will create the necessary conditions for entering in the stock market”.
Founded in 2005, biolog-id has patented technology that allows healthcare professionals to track, trace and manage sensitive healthcare products throughout their journey, from donor to patient. With more than 100 employees, the company currently operates in 14 countries throughout North America, Europe, the Middle East, India and the Asia-Pacific region.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005866/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 08:40:00 CET | Press release
The two largest global providers of massive IoT networks partner to provide a combined offering of LoRaWAN® and Cellular connectivity. 1NCE now integrates Netmore’s LoRaWAN into the 1NCE OS platform, allowing customers to use both services seamlessly through its software stack. The new network addresses 90% of the LPWAN market and offers an unparalleled ability to eliminate coverage blind spots around the globe. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 08:40:00 CET | Press release
The two largest global providers of massive IoT networks partner to provide a combined offering of LoRaWAN® and Cellular connectivity. 1NCE now integrates Netmore’s LoRaWAN into the 1NCE OS platform, allowing customers to use both services seamlessly through its software stack. The new network addresses 90% of the LPWAN market and offers an unparalleled ability to eliminate coverage blind spots around the globe 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two b
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 08:07:00 CET | Press release
Preview release invites industry collaboration on open source approach to functional safety assessment EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects o
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom